HIV/AIDS

HIV drug resistance

The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs is called HIV drug resistance (HIVDR). The consequences of HIVDR include treatment failure, need to start more costly second- and third- line treatments, increased health costs associated with these, spread of drug resistant HIV, and need to develop new anti-HIV drugs.
WHO, and its partner organizations and experts of HIVResNet group have developed a Global strategy for the surveillance and monitoring of HIV drug resistance. The strategy generates data on the emergence and transmission of HIVDR and equips countries with information to select first and second line antiretroviral therapy regimens.

Global Health Sector Strategy on HIV/AIDS 2011-2015: Let’s do what’s right for everyone

Global Hepatitis Programme

Contact us

World Health Organization
HIV/AIDS Department
20, Avenue Appia
CH-1211 Geneva 27
Switzerland
Email: hiv-aids@who.int